Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02423525 : Safety Study of Afatinib for Brain Cancer
PhasePhase 1
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Diagnosis

1. Dose Escalation Cohorts: Histologically confirmed diagnosis of brain cancer:

1. glioblastoma (GBM),

2. anaplastic astrocytoma (AA),

3. anaplastic oligodendroglioma (AO),

4. anaplastic mixed oligoastrocytoma (AMO),

5. low grade gliomas,

6. brain metastases,

7. meningiomas,

8. leptomeningeal metastases

9. chordomas

10. pituitary tumors

11. medulloblastomas

2. Expansion Cohort: Histologically confirmed diagnosis of high-grade glioma with
altered EGFR (e.g., amplification, mutation), including:

1. glioblastoma (GBM),

2. anaplastic astrocytoma (AA),

3. anaplastic oligodendroglioma (AO),

4. anaplastic mixed oligoastrocytoma (AMO)

- Has failed prior standard therapy including maximal safe surgical resection (when
appropriate for the specific cancer type), radiation therapy (when appropriate for the
specific cancer type), and systemic therapy (when appropriate for the specific cancer

- For diagnosis of GBM: has undergone maximal safe surgical resection, a course of
postoperative radiation therapy with concurrent temozolomide, and maintenance

- For diagnosis of meningioma: has no other option of standard therapy such as surgical
resection (partial or total resection) or radiation.

- Age 18 years and older.

- Karnofsky Performance Status = 60%.

- Adequate organ function, defined as all of the following:

1. Absolute neutrophil count (ANC) = 1.5 x 109/L.

2. Platelet count = 100 x 109/L.

3. Hemoglobin = 9.0 g/dL.

4. Total Bilirubin = 1.5 institution's upper limit of normal (ULN).

5. Aspartate amino transferase (AST) = 2.5 x institution's ULN.

6. Alanine amino transferase (ALT) = 2.5 x institution's ULN.

7. Alkaline phosphatase (ALP) = 2.5 x ULN unless considered tumor related.

- Recovered from any previous therapy-related toxicity to Grade 1 or to their clinical
baseline at study entry.

- Women of child-bearing potential has negative serum or urine pregnancy test before the
initiation of study drug dosing.

Exclusion Criteria:

- Insufficient time from prior therapy to study entry:

1. less than 28 days from whole-brain radiotherapy (WBRT) or stereotactic
radiosurgery (SRS);

2. less than 28 days from any investigational agent;

3. less than 28 days from prior cytotoxic therapy (except 23 days from prior
temozolomide, 14 days from vincristine (for GBM: 14 days from irinotecan or
topotecan), 42 days from nitrosoureas, 21 days from procarbazine, irinotecan or
topotecan administration);

4. less than 14 days from hormonal treatment

5. less than 7 days for non-cytotoxic agents, e.g., interferon, tamoxifen,
thalidomide, cis-retinoic acid, etc.

6. When radiation necrosis is suspected, standard of care confirmatory imaging, such
as MRI perfusion, magnetic resonance (MR) spectroscopy and or PET will be
performed, and patients with findings consistent with radiation necrosis will be

- Current or anticipated use of enzyme-inducing anti-epileptic drugs (EIAED).

- Major surgery within 4 weeks before starting study treatment or scheduled for surgery
during the projected course of the study.

- Known hypersensitivity to afatinib or its excipients.

- History or presence of clinically relevant cardiovascular abnormalities such as
uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA)
classification of 3 or 4, unstable angina or poorly controlled arrhythmia, or
myocardial infarction within 6 months prior to enrollment.

- Pregnant, nursing, or not using acceptable method of birth control.

- Any history of or concomitant condition that would compromise the patient's ability to
comply with the study or interfere with the evaluation of the efficacy and safety of
the test drug.

- Previous or concomitant malignancies at other sites, except effectively treated
non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ
or effectively treated malignancy that has been in remission for more than 3 years and
is considered to be cured.

- Known pre-existing interstitial lung disease.

- Known active hepatitis B infection (defined as presence of Hep B sAg and/ or Hep B
DNA), active hepatitis C infection (defined as presence of Hep C RNA) and/or known HIV

- Prior participation in a blinded afatinib clinical study, even if not assigned to
afatinib treatment.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557